How should kidney function be monitored during Streptozocin therapy?

Quantitative urine protein before every dose; Serum creatinine, phosphate, potassium, bicarbonate each cycle; Urine glucose / serum glucose discordance (glycosuria with euglycemia).

How can kidney injury from Streptozocin be prevented?

Hold the dose for significant proteinuria Dose reduction for renal dysfunction; consider divided/lower scheduling

Who is at higher risk of kidney injury from Streptozocin?

High cumulative dose; Pre-existing renal impairment; Volume depletion; Concurrent nephrotoxins; Re-challenge after a treatment interval.

Back to explorer

Printable monograph

Nitrosourea alkylator

Streptozocin

Zanosar · STZ

Nitrosourea alkylator · approved 1982 · 10 citations

Up to date· through 2026Teaching classic· proximal tubulopathy / Fanconi syndrome

A classic cause of proximal tubular injury and Fanconi syndrome — glycosuria, phosphaturia, aminoaciduria, and renal tubular acidosis. Now confined to niche islet-cell and neuroendocrine settings, it endures as a defining teaching example of drug-induced proximal tubulopathy.

Deeply sourced7/9 · 6 signals

Met: 10 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 45y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2026
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A glucose-mimicking nitrosourea that the proximal tubule eagerly takes up and pays for with Fanconi syndrome.

SevereNitrosourea alkylator

Metastatic pancreatic neuroendocrine (islet cell) carcinomaMalignant carcinoid tumors

§01

Signature kidney injury

Signature lesion

Fanconi Syndrome

Representative incidence30%

Nephrotoxicity is the major dose-limiting toxicity; transient proteinuria, tubular dysfunction and azotemia are common and a sizable minority develop clinically significant renal impairment, though precise rates are not uniformly quantified. Reported rate: decrease in estimated glomerular filtration rate of at least 25% during treatment in 30% — 111 patients (27 prospective + 84 retrospective) with locally advanced or metastatic well-differentiated digestive… (Legoux 2021, PMID 33751987).Source: Legoux et al., Clin Res Hepatol Gastroenterol 2021

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Tubular injury within weeks, worsening with cumulative dose.

Distilled from: “Within weeks of therapy; worsens with cumulative dose; abrupt AKI possible on re-challenge.”

RechallengeHigh recurrence risk

Abrupt AKI can recur on re-challenge.

Long-term outlook & thresholds

Renal recoveryOften partial recovery

Tubular injury caught early — rising proteinuria or a falling GFR — often stabilizes when the dose is reduced or the drug is stopped, but advanced damage can be irreversible.PMID 11219485 (opens PubMed in a new tab)

CKD trajectory.: Advanced proximal tubular damage can be irreversible and progress to chronic kidney disease.

Early-detection biomarkers

Serial urine protein (dipstick or protein–creatinine ratio) — Proximal tubular injury — the signal that tracks progression to renal failure. The one streptozocin marker with a published claim that watching it changes the outcome: the cited review states that progressive renal failure can be predicted by close monitoring of proteinuria and prevented by drug discontinuance. The evidence is narrative-review grade — no cohort, no threshold, no quantified lead time over creatinine — and a later review of the same drug class lists proteinuria alongside a rising creatinine and uraemia as heralding signs rather than ahead of them.PMID 3538860 (opens PubMed in a new tab)
Proximal-tubulopathy chemistry panel (phosphate, potassium, urate, bicarbonate, urine glucose) — Fanconi-type proximal tubular wasting — this agent's signature lesion. Hypophosphataemia, hypokalaemia, hypouricaemia, renal tubular acidosis, glucosuria and aminoaciduria are the listed additional signs of streptozocin nephrotoxicity, so the tubulopathy declares itself as a pattern across cheap routine chemistries. Review-grade rather than a validated panel: no incidence, no timing, and no demonstration that any single analyte moves before creatinine. Urate carries a specific trap — a case of oligoanuric failure from intraureteral uric-acid deposits occurred despite a normal serum urate, so the urinary measure, not the serum level, is the informative one.PMID 11219485 (opens PubMed in a new tab)

Long-term outcome and threshold data distilled from the agent's cited literature — educational, not a substitute for the primary sources.

Recovery across agents

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Fanconi Syndrome#1 · Signaturequalitative — no citable incidence
Global failure of proximal tubule reabsorption — glucosuria, phosphaturia and acidosis, classically from ifosfamide.
Acute Tubular NecrosisSecondaryqualitative — no citable incidence
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

30%incidence

SeveritySevere

ReversibilityPartially reversible

Evidence10 citations

Nephron map

Proximal TubuleBulk reabsorption + drug uptake (OCT2, OATs)

Distal Tubule / Collecting Duct

Fanconi Syndrome

Global failure of proximal tubule reabsorption — glucosuria, phosphaturia and acidosis, classically from ifosfamide.

§03

Kidney injury

Mechanism of kidney injury

GLUT2-mediated uptake concentrates the drug in S1-S3 proximal tubular cells, where alkylation and NAD+ depletion produce tubular cell injury and a proximal (type II) renal tubular acidosis / Fanconi picture - urinary wasting of phosphate, potassium, bicarbonate, glucose and amino acids. Defective tubular acidification is demonstrable functionally. Progressive tubular necrosis, squamous metaplasia and tubulointerstitial damage with azotemia follow cumulative dosing.

Clinical presentation

Proteinuria is typically the earliest sign, followed by glycosuria with normal blood glucose, aminoaciduria, hypophosphatemia, hypokalemia, hypouricemia, type II RTA, and rising creatinine. Abrupt AKI can follow a single additional dose after a previously tolerated course.

Management

Discontinue or reduce dose at the first sign of tubular proteinuria or falling GFR; supportive correction of electrolytes, phosphate and acidosis. Early injury may stabilize, but advanced damage can be irreversible and progress to chronic kidney disease.Lesion-level management framework

Risk factors

High cumulative dose
Pre-existing renal impairment
Volume depletion
Concurrent nephrotoxins
Re-challenge after a treatment interval

Prevention

Hold the dose for significant proteinuria
Dose reduction for renal dysfunction; consider divided/lower scheduling

Anticancer mechanism· how it treats cancer

Glucosamine-nitrosourea that alkylates DNA (and depletes NAD+ via PARP activation) and is preferentially taken up by GLUT2-expressing cells, the basis of both its islet-cell selectivity and its proximal tubular toxicity. Used for metastatic islet cell (pancreatic neuroendocrine) tumors and malignant carcinoid.

Note · Proteinuria monitoring before each cycle is the classic safeguard; the proximal tubular/Fanconi signature is well described in onconephrology reviews and pathology series.

§04

Clinical depth

Renal dose adjustment

Reduce dose and lengthen interval for impaired renal function; hold for new or worsening proteinuria or rising creatinine. Modern reviews emphasize scheduling (lower per-dose, fractionated) to cap cumulative tubular exposure in pNET.

Dialyzability & ESKD dosing

Small, renally cleared molecule; specific HD removal data are limited and it is rarely used in ESKD. Avoid in significant renal impairment rather than relying on dialytic clearance.

Differential diagnosis

Fanconi physiology (glycosuria with normal glucose, hypophosphatemia, hypouricemia, type II RTA, low-molecular-weight proteinuria) distinguishes streptozocin tubulopathy from glomerular proteinuria and from prerenal azotemia. The combination of euglycemic glycosuria plus phosphaturia is the fingerprint.

Monitoring

Quantitative urine protein before every dose
Serum creatinine, phosphate, potassium, bicarbonate each cycle
Urine glucose / serum glucose discordance (glycosuria with euglycemia)

Key trials & series

Hall-Craggs Hum Pathol 1982 - classic clinical AKI-on-re-challenge case with tubular pathology
Fennell & Falls Clin Nephrol 1981 - functional proof of the tubular acidification defect
Fazio Cancer Treat Rev 2026 - modern pNET scheduling to minimize nephrotoxicity

Clinical pearls

Check a urine protein BEFORE each dose - rising proteinuria is the earliest, most actionable warning.
A single re-challenge dose after a stable course can trigger abrupt acute renal failure; do not assume prior tolerance protects the kidney.
The same GLUT2 uptake that makes it islet-selective makes the proximal tubule the target organ.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the Nitrosourea alkylator class.

Hematologic

Cytopenias, thrombosis, TMA

Myelosuppression; secondary malignancy risk

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

Ifosfamide encephalopathy (chloroacetaldehyde)

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

High-dose cyclophosphamide cardiotoxicity

§05

References

8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

8 references · 1981–2026 · 1 since 2024

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 2

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedIndomethacin in streptozocin-induced nephrogenic diabetes insipidus.Delaney V et al. · Am J Kidney Dis 1987 · PMID 2949606Case report of streptozocin-induced glomerular plus proximal and distal tubular dysfunction presenting as nephrogenic diabetes insipidus with massive polyuria.CaseC · LimitedUric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity.Hricik DE et al. · Am J Med 1988 · PMID 2827466Case report of a man on high cumulative-dose streptozocin who developed oligoanuric acute renal failure from intraureteral uric acid deposits via the drug's uricosuric tubular effect.

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ADQIConventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupKidney Int 2026 · PMID 41881107Cisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Streptozocin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Trastuzumab deruxtecan

Enhertu · Antibody-drug conjugate (HER2/DXd)

Profile

Emerging AKI/proteinuria reports — under-published.

ATNFANCLYTE

Moderate#1 · 84% phenotype match

Imatinib

Gleevec · BCR-ABL TKI

Profile

Fluid retention; rare Fanconi and AKI.

LYTEFANCATN

Mild#2 · 78% phenotype match

Melphalan flufenamide (melflufen)

Pepaxto · Peptide-conjugated alkylator

Profile

Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.

ATNLYTE

Moderate#3 · 76% phenotype match

Ifosfamide

Ifex · Oxazaphosphorine alkylator

Profile

Chloroacetaldehyde → Fanconi syndrome.

FANCATNLYTE

Severe#4 · 73% phenotype match

Azacitidine

Vidaza · Hypomethylating agent

Profile

Proximal (type 2) RTA / Fanconi-like tubulopathy; overt AKI uncommon.

FANCATNLYTE

Moderate#5 · 72% phenotype match

Nedaplatin

Aqupla · Platinum agent

Profile

Second-gen platinum with reduced renal toxicity vs cisplatin.

ATNLYTE

Moderate#6 · 68% phenotype match

Compare Streptozocin with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Alkylating agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Streptozocin’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Streptozocin; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 54 clinical records among the 300 most-relevant of 305 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.